Arcadia Biosciences stock faces a Nasdaq compliance test

Published on 10/05/2026 at 09:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Arcadia Biosciences stock was last quoted at USD 0.29 on October 2, 2026, with a market value of USD 0.4 million. Second-quarter revenue reached USD 1.4 million, while net loss widened to USD 6.3 million.

RKDA, US0390143032, Illustration mit AI erstellt.

Arcadia Biosciences stock (ISIN US0390143032) was last at USD 0.29 on Nasdaq on October 2, 2026, leaving the company with a market capitalization of USD 0.4 million. The immediate issue is listing compliance, as Arcadia must submit a plan to address its Nasdaq equity shortfall by October 15, 2026.

Nasdaq deadline meets thin equity

According to StockTitan, Arcadia reported stockholders' equity of USD 633,000 as of June 30, 2026, against Nasdaq's USD 2.5 million continued-listing threshold. The equity figure was 74.7 percent below that requirement, making the compliance plan the central near-term corporate date.

The company also faces the separate Nasdaq minimum bid-price rule. Its stock continues trading under the symbol RKDA during an initial compliance period that runs through February 1, 2027, while the board has additional corporate tools available to address the share price.

Reverse split adds dilution risk

At the September 10, 2026 annual meeting, holders representing 52.3 percent of outstanding shares participated, according to StockTitan. Shareholders authorized a reverse stock split between 1-for-2 and 1-for-10, exercisable at the board's discretion before June 30, 2027.

The authorization can raise the quoted share price mechanically, but it does not increase the company's equity or operating cash generation. It therefore addresses the optics of the minimum bid-price rule more directly than the USD 633,000 equity deficit.

Losses outweigh quarterly sales

Arcadia's second-quarter 2026 revenue was USD 1.4 million, while net loss attributable to common stockholders widened to USD 6.3 million, according to StockTitan. First-half revenue reached USD 2.5 million, but the company also reported a USD 10.7 million first-half net loss, highlighting the gap between sales scale and financing-related losses.

The investor picture is consequently driven by three linked variables: the October 15 compliance submission, the eventual reverse-split ratio and the company's ability to fund operations while its equity base remains below Nasdaq's threshold. The next scheduled earnings event is listed for November 5, 2026 by UpTo.

RKDA stays near yearly low

RKDA was last at USD 0.29 on Nasdaq on October 2, 2026, with a 52-week range of USD 0.22 to USD 6.71 and volume of 209,632 shares. The stock's USD 0.4 million market capitalization makes the compliance decision and any financing action material for the entire listed equity base.